TrovaGene, Inc. Warrant
TROVW
TROVW was delisted on the 30th of May, 2017.
4 hedge funds and large institutions have $3.98M invested in TrovaGene, Inc. Warrant in 2015 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 0 closing their positions.
633% more call options, than puts
Call options by funds: $242K | Put options by funds: $33K
100% more funds holding
Funds holding: 2 → 4 (+2)
80% more capital invested
Capital invested by funds: $2.21M → $3.98M (+$1.77M)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$37.3K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$1.28K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$594 |
| 2 |
Millennium Management
New York
|
-$320 |
TROVW Hedge Fund Activity: Q2 2015 in Review
4 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in TrovaGene, Inc. Warrant (TROVW) for Q2 2015, worth a combined $3.98M — up 80% from $2.21M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new TROVW positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 2 trimmed.
The largest buyer was Morgan Stanley, opening a new position worth an estimated $37.3K. The largest seller was Tower Research Capital (TRC), cutting an estimated $594.
- 4 institutional investors held TrovaGene, Inc. Warrant (TROVW) as of Q2 2015, up from 2 in Q1 2015.
- Funds reported $3.98M of TrovaGene, Inc. Warrant stock for Q2 2015, up 80% quarter-over-quarter.
- 2 funds opened new TrovaGene, Inc. Warrant positions in Q2 2015 and 0 closed out, a net change of +2 holders.
- The largest TrovaGene, Inc. Warrant buyer in Q2 2015 was Morgan Stanley, an estimated $37.3K added.
- The largest TrovaGene, Inc. Warrant seller in Q2 2015 was Tower Research Capital (TRC), an estimated $594 sold.
Based on aggregated 13F filings for Q2 2015.